tert-Butyl 2-bromo-6,7-dihydro-5H-imidazo[1,2-a][1,4]diazepine-8(9H)-carboxylate

Catalog No. :
ACRCYA743
CAS No. :
1251000-20-0
Molecular Formula :
C12H18BrN3O2
Molecular Weight :
316.20

IUPAC Name:tert-butyl 2-bromo-6,7-dihydro-5H-imidazo[1,2-a][1,4]diazepine-8(9H)-carboxylate

tert-Butyl 2-bromo-6,7-dihydro-5H-imidazo[1,2-a][1,4]diazepine-8(9H)-carboxylate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100mg95%$593.00Login to see priceInquiryInquiry
250mg95%$989.00Login to see priceInquiryInquiry
500mg95%$1647.00Login to see priceInquiryInquiry
1g95%$2471.00Login to see priceInquiryInquiry
5g95%$7412.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Nametert-Butyl 2-bromo-6,7-dihydro-5H-imidazo[1,2-a][1,4]diazepine-8(9H)-carboxylate
IUPAC Nametert-butyl 2-bromo-6,7-dihydro-5H-imidazo[1,2-a][1,4]diazepine-8(9H)-carboxylate
Molecular FormulaC12H18BrN3O2
Molecular Weight316.20
SMILESO=C(N1CC2=NC(Br)=CN2CCC1)OC(C)(C)C
InChI KeySKLYANWIAXJMDS-UHFFFAOYSA-N
Synonym1251000-20-0 | tert-butyl 2-bromo-5H,6H,7H,8H,9H-imidazo[1,2-a][1,4]diazepine-8-carboxylate | Tert-butyl 2-bromo-5,6,7,9-tetrahydroimidazo[1,2-a][1,4]diazepine-8-carboxylate | tert-Butyl 2-bromo-6,7-dihydro-5H-imidazo[1,2-a][1,4]diazepine-8(9H)-carboxylat
CAS No.1251000-20-0
PubChem CID135396465

Synthetic Route by SureRoute

1. ACRCYA743 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACRCYA743 route product structure diagram
    ACRCYA7431251000-20-0
Inquiry

2. ACRCYA743 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACRCYA743 route product structure diagram
    ACRCYA7431251000-20-0
Inquiry

Comments (0)